Prevention of Osteoporosis Associated With Chronic Glucocorticoid Therapy
- Michael P. Heffernan, Commentary by, MD;
- Kenneth G. Saag, MD, MSc;
- June K. Robinson, MD;
- Jeffrey P. Callen, MD
- Author Affiliations: Division of Dermatology, Wright State University Boonshoft School of Medicine, Dayton, Ohio (Dr Heffernan); Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama, Birmingham (Dr Saag); Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Ill (Dr Robinson); and Division of Dermatology, Department of Medicine, University of Louisville, Louisville, Ky (Dr Callen). Dr Robinson is the Editor, Archives of Dermatology and Dr Callen is the Associate Editor, Archives of Dermatology.
- Corresponding Author: Jeffrey P. Callen, MD, University of Louisville School of Medicine, 310 E Broadway, Louisville, KY 40202 (jefca{at}aol.com).
Since this article does not have an abstract, we have provided the first 150 words of the full text.
ARCHIVES OF DERMATOLOGY
Glucocorticoid-Induced Bone Loss in Dermatologic Patients: An Update
Brett T. Summey, MD; Gil Yosipovitch, MD
Objective: To raise awareness of the new treatment options and current recommendations among dermatologists treating patients with
systemic corticosteroids.
Data Sources: MEDLINE peer-reviewed publications.
Study Selection: English language and clinical pertinence to corticosteroid-induced osteoporosis.
Data Extraction: Pertinent information on pathophysiologic, epidemiologic, clinical trial, cost-effectiveness, and treatment option data
regarding corticosteroid-induced osteoporosis.
Data Synthesis: Comprehensive summary of published data on the pathophysiologic, epidemiologic, clinical, and treatment data and current
practice guidelines regarding corticosteroid-induced osteoporosis; creation of an algorithmic management approach for patients
treated with long-term oral corticosteroids.
Conclusions: Glucocorticoid-induced bone loss is the most predictable and debilitating complication of prolonged administration of systemic
corticosteroids. Every dermatologist prescribing systemic corticosteroids must be aware of corticosteroid-induced osteoporosis
and ensure that every patient is receiving general measures to prevent it. …
